Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?

Osimertinib, a third-generation (3G) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is now considered the standard of care for the first-line (1L) treatment of advanced EGFR+ NSCLC due to statistically significant improved progression-free survival (PFS) and overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shannon S, Ou, Sai-hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617553/
https://www.ncbi.nlm.nih.gov/pubmed/36317157
http://dx.doi.org/10.2147/LCTT.S385437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617553/
https://www.ncbi.nlm.nih.gov/pubmed/36317157
http://dx.doi.org/10.2147/LCTT.S385437

Ejemplares similares